References
- Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453–2463.
- Jillella AP, Dainer PM, Kallab AM, et al. Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. Am J Hematol 2002;71:219–222.
- GlaxoSmithKline USA [Internet]. Available from: http://us.gsk.com/products/assets/us_bexxar.pdf
- Fujifilm RI Pharma Co., Ltd. [Internet]. Available from: www.info.pmda.go.jp/go/interview/1/630004_4291414G1020_1_002_1F
- Watanabe T, Terui S, Itoh K, et al. Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate [(90)Y- ibritumomab tiuxetan] in relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2005;96:903–910.
- Giusti DL, Hayton WL. Dosage regimen adjustment. Drug Intell Clin Pharmacy 1973;7:382–387.
- The Japanese Society for Dialysis Therapy [Internet]. Available from: http://docs.jsdt.or.jp/overview/
- Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17: 3793–3803.
- Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262–3269.
- Tobinai K, Watanabe T, Ogura M, et al. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2009;100:158–164.
- Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439–1447.
- Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46(Suppl. 1):99S–106S.
- Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847–1856.
- Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44: 465–474.
- Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;109: 1804–1810.